Tags Archive Navigation
icon
-
Media ReleaseNovartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021
-
Media ReleaseNovartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
-
Media ReleaseSandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
-
Media ReleaseNovartis completes tender offer for all outstanding shares of The Medicines Company
-
Media ReleaseNovartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
-
Media ReleaseNovartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
-
Media ReleaseNovartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculaires
-
Media ReleaseNovartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
-
Media ReleaseNovartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
-
Media ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 15
- › Next page